PHARMA SANTE DEVELOPPEMENT : revenue, balance sheet and financial ratios

PHARMA SANTE DEVELOPPEMENT is a French company founded 25 years ago, specialized in the sector Centrales d'achat non alimentaires. Based in MARSEILLE (13011), this company of category PME shows in 2023 a revenue of 2.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMA SANTE DEVELOPPEMENT (SIREN 432743862)
Indicator 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 2 376 413 € 1 715 896 € 2 002 432 € 2 380 360 € 1 766 355 € 2 453 990 € 2 869 879 € 3 491 886 €
Net income 347 133 € -785 325 € -245 185 € 218 526 € -245 040 € 296 913 € 129 055 € 779 189 €
EBITDA 548 135 € -752 672 € -237 185 € 452 523 € -68 068 € 694 602 € 423 198 € 1 558 744 €
Net margin 14.6% -45.8% -12.2% 9.2% -13.9% 12.1% 4.5% 22.3%

Revenue and income statement

In 2023, PHARMA SANTE DEVELOPPEMENT achieves revenue of 2.4 M€. Revenue is declining over the period 2016-2023 (CAGR: -5.3%). Vs 2022, growth of +38% (1.7 M€ -> 2.4 M€). After deducting consumption (0 €), gross margin stands at 2.4 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 548 k€, representing 23.1% of revenue. Positive scissor effect: EBITDA margin improves by +66.9 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 347 k€, i.e. 14.6% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2023) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

2 376 413 €

Gross margin (2023) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

2 376 413 €

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

548 135 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

538 747 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

347 133 €

EBITDA margin (2023) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

23.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1427%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 2%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 14.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1427.269%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

2.272%

Cash flow / Revenue (2023) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

14.856%

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

8.219

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

4.4%

Solvency indicators evolution
PHARMA SANTE DEVELOPPEMENT

Sector positioning

Debt ratio
1427.27 2023
2021
2022
2023
Q1: 0.02
Med: 9.41
Q3: 85.65
Watch

In 2023, the debt ratio of PHARMA SANTE DEVELOPPEMENT (1427.27) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
2.27% 2023
2021
2022
2023
Q1: 13.67%
Med: 31.89%
Q3: 57.94%
Watch

In 2023, the financial autonomy of PHARMA SANTE DEVELOPPEMENT (2.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
8.22 years 2023
2021
2022
2023
Q1: 0.0 years
Med: 0.03 years
Q3: 2.12 years
Watch +51 pts over 3 years

In 2023, the repayment capacity of PHARMA SANTE DEVELOPPEMENT (8.22) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 150.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 17.7x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

150.474

Interest coverage (2023) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

17.68

Liquidity indicators evolution
PHARMA SANTE DEVELOPPEMENT

Sector positioning

Liquidity ratio
150.47 2023
2021
2022
2023
Q1: 120.0
Med: 168.48
Q3: 310.0
Average +8 pts over 3 years

In 2023, the liquidity ratio of PHARMA SANTE DEVELOPPEMENT (150.47) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
17.68x 2023
2021
2022
2023
Q1: 0.0x
Med: 0.54x
Q3: 11.1x
Excellent +50 pts over 3 years

In 2023, the interest coverage of PHARMA SANTE DEVELOPPEMENT (17.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 867 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1037 days. Excellent situation: suppliers finance 170 days of the operating cycle (retail model). Overall, WCR represents 1037 days of revenue, i.e. 6.8 M€ to permanently finance. Over 2016-2023, WCR increased by +255%, requiring additional financing.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

6 845 590 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

867 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

1037 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2023) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

1037 j

WCR and payment terms evolution
PHARMA SANTE DEVELOPPEMENT

Positioning of PHARMA SANTE DEVELOPPEMENT in its sector

Comparison with sector Centrales d'achat non alimentaires

Valuation estimate

Based on 85 transactions of similar company sales (all years), the value of PHARMA SANTE DEVELOPPEMENT is estimated at 595 398 € (range 321 819€ - 2 231 596€). With an EBITDA of 548 135€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.32x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2023
85 tx
321k€ 595k€ 2231k€
595 398 € Range: 321 819€ - 2 231 596€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
548 135 € × 1.0x
Estimation 539 505 €
296 170€ - 2 391 076€
Revenue Multiple 30%
2 376 413 € × 0.32x
Estimation 767 732 €
427 602€ - 1 824 335€
Net Income Multiple 20%
347 133 € × 1.4x
Estimation 476 634 €
227 270€ - 2 443 789€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Centrales d'achat non alimentaires)

Compare PHARMA SANTE DEVELOPPEMENT with other companies in the same sector:

Voir toutes les statistiques du secteur Centrales d'achat non alimentaires

Frequently asked questions about PHARMA SANTE DEVELOPPEMENT

What is the revenue of PHARMA SANTE DEVELOPPEMENT ?

The revenue of PHARMA SANTE DEVELOPPEMENT in 2023 is 2.4 M€.

Is PHARMA SANTE DEVELOPPEMENT profitable?

Yes, PHARMA SANTE DEVELOPPEMENT generated a net profit of 347 k€ in 2023.

Where is the headquarters of PHARMA SANTE DEVELOPPEMENT ?

The headquarters of PHARMA SANTE DEVELOPPEMENT is located in MARSEILLE (13011), in the department Bouches-du-Rhone.

Where to find the tax return of PHARMA SANTE DEVELOPPEMENT ?

The tax return of PHARMA SANTE DEVELOPPEMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMA SANTE DEVELOPPEMENT operate?

PHARMA SANTE DEVELOPPEMENT operates in the sector Centrales d'achat non alimentaires (NAF code 46.19A). See the 'Sector positioning' section above to compare the company with its competitors.